Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Concizumab multiple-dose subcutaneous trial in adults with haemophilia A
NL-OMON42365Withdrawn
- Sponsor
- Novo Nordisk
- Start
- Aug 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Randomised, double-blind trial in hemophilia A comparing Concizumab with Placebo (2 arms). Primary endpoint: Number of adverse events. Planned start Aug 2015; status: withdrawn.
02
Drugs
concizumab
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NL-OMON42365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42365.